Mystery Rozerem ads earn brand infamy

Share this article:
Rozerem reminder ad.
Rozerem reminder ad.

Takeda's Rozerem took top honors in a UK consumer advocacy group's International Bad Product Awards.

London-based Consumers International, which bills itself as a global federation of consumer groups, named the sleeping pill as its worst of the worst on the merits of a 10-second TV reminder ad hawking the drug for school children which ran in September 2006.

The sketchy spot, unrelated to the brand's surreal main “Your Dreams Miss You” campaign, aired only about four times on MSNBC and was disavowed by Takeda and its advertising agencies after an FDA rebuke. Rozerem is not indicated for pediatric use, the spot was not submitted to FDA for vetting and TV reminder ads are a no-no under PhRMA DTC guidelines. Takeda Pharmaceuticals North America is an international affiliate of PhRMA, though the company was not a signatory to those guidelines.

Consumers International said in a release: “This case demonstrates the lengths to which some drug companies will go to increase sales of their products, how direct-to-consumer advertising can promote irrational drug use, and how weak regulation can foster irresponsible corporate behavior.” 

Runners-up included Coca-Cola, for Dasani (“Repackaging tap water”), Kellogg's (“Advertising junk food to kids”) and Mattel, for its handling of a toy recall.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.